Darrell Pardi, MD
Gastroenterology · Rochester, MNNPI 1801874169
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,993 of the $16,579 with a category attached, or 72.3%. 8 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 58.4% of the total. Reporting peaked in 2023 at $12,947 and has fallen 99.8% since, to $28 in 2025.
Across 36 payments — averaging $460.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$10K
- Boehringer Ingelheim$2K
- Boston Scientific$1K
- Seres Therapeutics, Inc.$1K
- AbbVie$996
- Otsuka Pharmaceutical Development & Commercialization, Inc.$813
- plus $863 from 2 others
Across 46 payments — averaging $2823.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$65K
- Takeda Pharmaceuticals U.S.A., Inc.$46K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$15K
- Janssen Research & Development, LLC$4K
What the payments were for
- Consulting fees$11,99372%
- Travel & lodging$3,61122%
- Food & beverage$9746%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 15 | $9,688 |
| Boehringer Ingelheim | 1 | $1,500 |
| Boston Scientific | 9 | $1,483 |
| Seres Therapeutics, Inc. | 5 | $1,236 |
| AbbVie | 2 | $996 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $813 |
| Eli Lilly | 1 | $800 |
| Aimmune Therapeutics, Inc. | 2 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REBYOTA$9,303
- EXALT Model D$1,323
- VOWST$1,113
- SPYGLASS$103
How this compares
$16,579 in reported general payments places this provider in the 85th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 40 | $1,154,668 |
| Vancomycin Hcl | 15 | $1,193 |
| Atorvastatin Calcium | 22 | $396 |
| Pantoprazole Sodium | 15 | $367 |
| Amlodipine Besylate | 22 | $274 |
| Levothyroxine Sodium | 12 | $169 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Rochester
- John KisielRochester$856K
- Christopher GostoutRochester$299K
- Edward LoftusRochester$282K
- Alina AllenRochester$277K
- Todd BaronRochester$270K
- Sahil KhannaRochester$242K
- Joseph MurrayRochester$234K
- Andres AcostaRochester$224K
- David LarsonRochester$142K
- Ibrahim HanounehRochester$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.